» Articles » PMID: 26576077

Hepatic Immune Tolerance Induced by Hepatic Stellate Cells

Overview
Specialty Gastroenterology
Date 2015 Nov 18
PMID 26576077
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The liver, which is a metabolic organ, plays a pivotal role in tolerance induction. Hepatic stellate cells (HpSCs), which are unique non-parenchymal cells, exert potent immunoregulatory activity during cotransplantation with allogeneic islets effectively protecting the islet allografts from rejection. Multiple mechanisms participate in the immune tolerance induced by HpSCs, including the marked expansion of myeloid-derived suppressor cells (MDSCs), attenuation of effector T cell functions and augmentation of regulatory T cells. HpSC conditioned MDSC-based immunotherapy has been conducted in mice with autoimmune disease and the results show that this technique may be promising. This article demonstrates how HpSCs orchestrate both innate immunity and adaptive immunity to build a negative network that leads to immune tolerance.

Citing Articles

Vitamin A Metabolism and Resistance of Hepatic Metastases to Immunotherapy.

Jones P, Von Hoff D Mol Cancer Ther. 2024; 24(3):345-353.

PMID: 39363636 PMC: 11876961. DOI: 10.1158/1535-7163.MCT-24-0367.


Role of Cytokines on the Progression of Liver Fibrosis in Mice Infected with .

Tian F, Jiang T, Qi X, Zhao Z, Li B, Aibibula M Infect Drug Resist. 2022; 14:5651-5660.

PMID: 34992391 PMC: 8714463. DOI: 10.2147/IDR.S344508.


Hepatic Stellate Cell: A Double-Edged Sword in the Liver.

Luo N, Li J, Wei Y, Lu J, Dong R Physiol Res. 2021; 70(6):821-829.

PMID: 34717063 PMC: 8815467. DOI: 10.33549/physiolres.934755.


Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment.

Liu Z, Liu J, Staiculescu D, Chen J Ther Adv Med Oncol. 2021; 13:17588359211018026.

PMID: 34104226 PMC: 8150670. DOI: 10.1177/17588359211018026.


Fibrinogen-like protein 2 promotes the accumulation of myeloid-derived suppressor cells in the hepatocellular carcinoma tumor microenvironment.

Liu B, Bao Z, Zhu J, Liu H Oncol Lett. 2020; 21(1):47.

PMID: 33281958 PMC: 7709556. DOI: 10.3892/ol.2020.12308.


References
1.
Carambia A, Freund B, Schwinge D, Heine M, Laschtowitz A, Huber S . TGF-β-dependent induction of CD4⁺CD25⁺Foxp3⁺ Tregs by liver sinusoidal endothelial cells. J Hepatol. 2014; 61(3):594-9. DOI: 10.1016/j.jhep.2014.04.027. View

2.
Schildberg F, Kurts C, Knolle P . Prominent regulatory but weak antigen-presenting cell function of hepatic stellate cells. Hepatology. 2011; 54(3):1108. DOI: 10.1002/hep.24565. View

3.
Bhatt S, Shen G, Li Y, Qian S, Ragni M, Lu L . Hepatic stellate cell-conditioned myeloid cells provide a novel therapy for prevention of factor VIII antibody formation in mice. Exp Hematol. 2014; 43(4):277-85. DOI: 10.1016/j.exphem.2014.12.001. View

4.
Dusabineza A, Najimi M, Van Hul N, Legry V, Khuu D, van Grunsven L . Hepatic Stellate Cells Improve Engraftment of Human Primary Hepatocytes: A Preclinical Transplantation Study in an Animal Model. Cell Transplant. 2015; 24(12):2557-71. DOI: 10.3727/096368915X686788. View

5.
Almand B, Clark J, Nikitina E, Van Beynen J, English N, Knight S . Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2000; 166(1):678-89. DOI: 10.4049/jimmunol.166.1.678. View